Case study backs Argent's cannabinoid for epilepsy

The Australian

10 hours ago

Case report shows clinical benefits of Argent's CannEpil in a paediatric patient with Lennox-Gastaut Syndrome
Peer-reviewed case report published in International Journal of Clinical Medicine & Case Reports
Significant reduction in seizure frequency and severity following treatment with reported improved quality of life
Special Report: Publication of a peer-reviewed case report highlights the therapeutic potential of Argent BioPharma's proprietary cannabinoid therapy CannEpil in treatment-resistant epilepsy.
The article titled Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination was published in the International Journal of Clinical Medicine & Case Reports.
It details the successful treatment of a paediatric patient with Lennox-Gastaut Syndrome (LGS) using CannEpil, a proprietary CBD/THC isolate formulation produced under EU-GMP standards by Argent BioPharma (ASX:RGT).
LGS is a severe and complex form of epilepsy that typically begins in early childhood and is characterised by multiple types of seizures, developmental delays and its resistance to standard anti-epileptic treatments.
The study, authored by Argent's VP of medical development Dr Jonathan Grunfeld and medical researcher Dr Jasna Jarc, describes a significant improvement in the patient's condition and quality of life, including:
A reduction in seizure clusters and daily seizure frequency;
Recovery of speech, fine motor skills and independent mobility; and
Reintegration into a full-time educational environment
Case study builds evidence for CannEpil's clinical and strategic potential
Argent said the latest peer-reviewed case study added to the growing body of real-world evidence supporting CannEpil's application in complex epilepsy syndromes.
It also highlights the advantages of using pharmaceutical-grade isolate combinations over full-spectrum botanical preparations, providing more precise dosing and improved safety profiles.
The case study also aligns with the indication for Epidiolex, which is currently the only US Food and Drug Administration (FDA) approved cannabinoid treatment for LGS.
The milestone regulatory approval underpinned Nasdaq-listed Jazz Pharmaceuticals' ~US$7.2 billion acquisition of Epidolex's developer in 2021 GW Pharmaceuticals plc.
While CannEpil is not yet positioned to compete with Epidiolex on regulatory validation, Argent said the therapy was emerging as a potential next-generation cannabinoid treatment for refractory epilepsy, particularly in patients who did not respond to CBD-only formulations.
Supported by clinical case data and head-to-head comparative research, CannEpil aims to deliver meaningful seizure reduction, improved quality of life and better patient tolerability at lower doses, while maintaining pharmaceutical-grade consistency.
"This case exemplifies the transformative impact a rigorously formulated cannabinoid therapy can have on patients for whom standard treatments have failed,' Grunfeld said.
'CannEpil's precision, purity and clinical consistency are central to its success."
This article was developed in collaboration with Argent BioPharma, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.